Premature newborns' need for transfusions declines with ESA use

06/18/2013 | Medscape (free registration)

Treating preterm infants with an erythropoiesis-stimulating agent such as darbepoetin alfa can help decrease the use of red blood cell transfusions, according to a study in the journal Pediatrics. Infants given the drugs in a trial at high-altitude hospitals were given fewer transfusions. Fifty-nine percent of infants administered darbepoetin alfa and 52% of infants given erythropoietin did not receive transfusions, compared with 38% for the placebo group.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA
Assistant General Counsel, Regulatorya
Cardinal Health
Waukegan, IL
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA